logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5115.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5115.produseast1
MSF Science Portal | Collections | MSF Science Portal
MSF Science Portal

MSF Science Portal

While Médecins Sans Frontières (MSF) is known mostly for providing direct medical aid to people affected by conflict, epidemics, disasters, or exclusion from health services, we also conduct research aimed at improving patient care and advocating for evidence-based policy and practices. To this end we conduct hundreds of research studies each year, publish extensively in peer-reviewed journals, and present our findings at scientific conferences around the world, including several annual MSF-organized events.


With the MSF Science Portal we introduce a new platform that aims to be a « one-stop shop » for content related to this work, so that users anywhere can easily find, browse, access, share and use the knowledge our research generates. Alongside frequent updates of new publications, conference materials, reports and featured content, we will continue to develop this site and to expand its range of content. To learn more about the Portal and what it offers, check out the short videos and slide presentation in this collection.

Collection Content

Conference Material
|
Video

A tour of the MSF Science Portal

Kahn P, Burgess B, Leader C, Chaudhuri J
2022-05-10 • MSF Scientific Days International 2022
2022-05-10 • MSF Scientific Days International 2022
Conference Material
|
Video

The MSF Science Portal: a “one-stop shop” for our public research content

Kahn P, Brooks JR, Leader C, Hoyt O
2021-05-20 • MSF Scientific Days International 2021: Innovation
2021-05-20 • MSF Scientific Days International 2021: Innovation
Conference Material
|
Abstract

The MSF Science Portal: A “one-stop shop” for our public research content

Kahn P, Brooks JR, Leader C, Hoyt O
2021-05-20 • MSF Scientific Days International 2021: Innovation
2021-05-20 • MSF Scientific Days International 2021: Innovation
CHALLENGE/OPPORTUNITY
Each year MSF conducts hundreds of research studies to help fill gaps in the medical knowledge needed for our humanitarian work, and then disseminates the findi...
Conference Material
|
Slide Presentation

The MSF Science Portal: A “one-stop shop” for our public research content

Kahn P, Brooks JR, Leader C, Hoyt O
2021-05-20 • MSF Scientific Days International 2021: Innovation
2021-05-20 • MSF Scientific Days International 2021: Innovation

See more collections

World NTD Day

World NTD Day

Neglected tropical diseases (NTDs) impact nearly 1.7 billion people each year, causing serious illness or lifelong disability among many—often leading to stigma and exclusion—and killing an estimated 200,000. The vast majority of sufferers live in the world’s poorest countries.


The World Health Organization’s NTD roadmap 2021-2030 aims to address 20 tropical diseases through prevention, control, elimination, and/or eradication. But despite some progress, reaching all its targets will take better, far more accessible diagnostics and treatments along with more robust strategies, political commitment and resources.


To mark World NTD Day, this collection spotlights work by MSF and collaborators on improving approaches to snakebite envenoming, kala azar and noma. One study presents an innovative artificial intelligence-based snakebite diagnostic tool, while others evaluate shorter, less toxic drug regimens or different models of care. Several commentaries advocate for national/regional strategies adapted to contexts ranging from remote villages to active conflict zones. Another crucial factor is the climate crisis, which is intensifying the transmission and geographic spread of many NTDs.

TB-PRACTECAL Trial—Evidence for a shorter, safer, more effective treatment for drug-resistant tuberculosis

TB-PRACTECAL Trial—Evidence for a shorter, safer, more effective treatment for drug-resistant tuberculosis
Drug-resistant tuberculosis (DR-TB) remains an especially deadly form of the ancient scourge of TB, while current treatments are long, toxic, and ineffective for half of all patients. Aiming to change this unacceptable status quo, in the mid-2010’s MSF and partners launched three clinical trials to test novel regimens containing the first new TB drugs in decades. On 22 December 2022 the New England Journal of Medicine published findings from TB-PRACTECAL, a three-country randomized controlled trial, showing that a shorter regimen is safer and cured 89% of DR-TB patients, compared with 52% on the standard of care. These findings have already been incorporated into the World Health Organization’s new TB treatment guidelines. A separate study shows that the new regimen is also more cost-effective. Alongside these results the content collection linked below highlights other aspects of the trial, from community engagement strategies that helped shape TB-PRACTECAL to setbacks arising from the Covid-19 pandemic. It also examines urgent challenges in scaling up access to these life-saving drugs, including affordability and patent barriers.
MSF logo

World Malaria Day 2022
No description available
View All Collections